Company intelligence / Profile preview
Voronoi Solutions
Incheon, Incheon Metropolitan City, South Koreapitneybowes.com ↗
- Ownership
- Private
- Employees
- ~147
- Development stage
- Other
01
Overview
Voronoi specializes in developing innovative small molecule kinase inhibitors and protein degrader drugs targeting oncology and immunology indications. Lead assets include BBI‑02 for atopic dermatitis, VRN‑10 for HER₂-positive solid tumors, and VRN‑11 for non-small cell lung cancer. Most programs are early-stage with no reported pivotal clinical results yet.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small moleculeProtein degrader drugs (Proteolysis-targeting chimera therapy)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Voronoi Solutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Voronoi Solutions.